Hệ thống vận chuyển thuốc nano α-cyperone dạng liposome hướng tới bề mặt tiêu hủy xương ức chế sự phân hóa tế bào tạo xương và tiến triển của loãng xương thông qua trục PI3K/Akt

Weitzmann, M. N.; Ofotokun, I. Physiological and pathophysiological bone turnover - role of the immune system. Nat. Rev. Endocrinol. 2016, 12, 518–532. Eastell, R.; O’Neill, T. W.; Hofbauer, L. C.; Langdahl, B.; Reid, I. R.; Gold, D. T.; Cummings, S. R. Postmenopausal osteoporosis. Nat. Rev. Dis. Primers 2016, 2, 16069. Sipos, W.; Pietschmann, P.; Rauner, M. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immunemediated bone and joint diseases. Curr. Med. Chem. 2008, 15, 127–136. Li, H. X.; Xiao, Z. S.; Quarles, L. D.; Li, W. Osteoporosis: Mechanism, molecular target and current status on drug development. Curr. Med. Chem. 2021, 28, 1489–1507. Lee, S.; Kim, G. J.; Kwon, H.; Nam, J. W.; Baek, J. Y.; Shim, S. H.; Choi, H.; Kang, K. S. Estrogenic effects of extracts and isolated compounds from belowground and aerial parts of Spartina anglica. Mar. Drugs 2021, 19, 210. Zeytinoglu, M.; Naaman, S. C.; Dickens, L. T. Denosumab discontinuation in patients treated for low bone density and osteoporosis. Endocrinol. Metab. Clin. North Am. 2021, 50, 205–222. Black, D. M.; Rosen, C. J. Postmenopausal osteoporosis. N. Engl. J. Med. 2016, 374, 254–262. Horn, C.; Vediyappan, G. Anticapsular and antifungal activity of α-Cyperone. Antibiotics 2021, 10, 51. Huang, B.; Liu, J.; Fu, S.; Zhang, Y.; Li, Y.; He, D.; Ran, X.; Yan, X.; Du, J.; Meng, T.; Gao, X.; Liu, D. α-Cyperone Attenuates H(2)O(2)-Induced Oxidative Stress and Apoptosis in SH-SY5Y Cells via Activation of Nrf2. Front Pharmacol 2020, 11 281. Huang, B. X.; He, D. W.; Chen, G. X.; Ran, X.; Guo, W. J.; Kan, X. C.; Wang, W.; Liu, D. F.; Fu, S. P.; Liu, J. X. α-Cyperone inhibits LPS-induced inflammation in BV-2 cells through activation of Akt/Nrf2/HO-1 and suppression of the NF-κB pathway. Food Funct. 2018, 9, 2735–2743. Zhang, H. W.; Li, S. L.; Lu, J. J.; Jin, J.; Zhu, G. S.; Wang, L. B.; Yan, Y. Z.; He, L. J.; Wang, B.; Wang, X. Y. et al. α-Cyperone (CYP) down-regulates NF-κB and MAPKs signaling, attenuating inflammation and extracellular matrix degradation in chondrocytes, to ameliorate osteoarthritis in mice. Aging 2021, 13, 17690–17706. Kum, C. J.; Kim, E. Y.; Kim, J. H.; Lee, B.; Min, J. H.; Heo, J.; Kim, J. H.; Yeom, M.; Sohn, Y.; Jung, H. S. Cyperus rotundus L. extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat. J. Ethnopharmacol. 2017, 205, 186–194. Nirwan, N.; Nikita; Sultana, Y.; Vohora, D. Liposomes as multifaceted delivery system in the treatment of osteoporosis. Expert Opin. Drug Deliv. 2021, 18, 761–775. Wang, D.; Miller, S. C.; Shlyakhtenko, L. S.; Portillo, A. M.; Liu, X. M.; Papangkorn, K.; Kopečková, P.; Lyubchenko, Y.; Higuchi, W. I.; Kopeček, J. Osteotropic Peptide that differentiates functional domains of the skeleton. Bioconjug. Chem. 2007, 18, 1375–1378. Zhang, G.; Guo, B. S.; Wu, H.; Tang, T.; Zhang, B. T.; Zheng, L. Z.; He, Y. X.; Yang, Z. J.; Pan, X. H.; Chow, H. et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat. Med. 2012, 18, 307–314. Armas, L. A. G.; Recker, R. R. Pathophysiology of osteoporosis: New mechanistic insights. Endocrinol. Metab. Clin. North Am. 2012, 41, 475–486. Zhang, M. J.; Yu, J. Y.; Liu, A.; Liu, Q. Q.; Sun, T.; Li, X.; Du, Y. Y.; Li, J. M.; Wang, B.; Yang, Q. Luteolin in the Qi Bi Anshen decoction improves propionic acid-induced autism-like behavior in rats by inhibiting LRP1/MMP9. Phytomedicine 2023, 118, 154965. Wang, T. X.; Chen, M.; Li, H. X.; Ding, G. Y.; Song, Y. F.; Hou, B.; Yao, B.; Wang, Z. X.; Hou, Y. L.; Liang, J. Q. et al. Repositioning of clinically approved drug Bazi Bushen capsule for treatment of Aizheimer’s disease using network pharmacology approach and in vitro experimental validation. Heliyon 2023, 9, e17603. Jia, X. Y.; He, Y. H.; Li, L.; Xu, D. L. Pharmacological targeting of gastric mucosal barrier with traditional Chinese medications for repairing gastric mucosal injury. Front. Pharmacol. 2023, 14, 1091530. Alam, S. S. M.; Samanta, A.; Uddin, F.; Ali, S.; Hoque, M. Tanshinone IIA targeting cell signaling pathways: A plausible paradigm for cancer therapy. Pharmacol. Rep. 2023, 75, 907–922. Yang, F. G.; Zhang, S. H.; Tian, D. M.; Zhou, G. R.; Tang, X. Y.; Miao, X. L.; He, Y.; Yao, X. S.; Tang, J. S. Deciphering chemical and metabolite profiling of Chang-Kang-Fang by UPLC-Q-TOF-MS/MS and its potential active components identification. Chin. J. Nat. Med. 2023, 21, 459–480. Liu, X. S. B. J.; Jin, X. T.; Yu, D.; Liu, G. Suppression of NLRP3 and NF-κB signaling pathways by α-Cyperone via activating SIRT1 contributes to attenuation of LPS-induced acute lung injury in mice. Int. Immunopharmacol. 2019, 76, 105886. Jung, S. H.; Kim, S. J.; Jun, B. G.; Lee, K. T.; Hong, S. P.; Oh, M. S.; Jang, D. S.; Choi, J. H. α-Cyperone, isolated from the rhizomes of Cyperus rotundus, inhibits LPS-induced COX-2 expression and PGE2 production through the negative regulation of NFκB signalling in RAW 264.7 cells. J. Ethnopharmacol. 2013, 147, 208–214. Huang, B. X.; Hu, G. Q.; Zong, X. F.; Yang, S.; He, D. W.; Gao, X. Y.; Liu, D. F. α-Cyperone protects dopaminergic neurons and inhibits neuroinflammation in LPS-induced Parkinson’s disease rat model via activating Nrf2/HO-1 and suppressing NF-κB signaling pathway. Int. Immunopharmacol. 2023, 115, 109698. Pei, X. D.; Yao, H. L.; Shen, L. Q.; Yang, Y.; Lu, L.; Xiao, J. S.; Wang, X. Y.; He, Z. L.; Jiang, L. H. α-Cyperone inhibits the proliferation of human cervical cancer HeLa cells via ROS-mediated PI3K/Akt/mTOR signaling pathway. Eur. J. Pharmacol. 2020, 883, 173355. Hopkins, A. L. Network pharmacology: The next paradigm in drug discovery. Nat. Chem. Biol. 2008, 4, 682–690. Lee, S. E.; Woo, K. M.; Kim, S. Y.; Kim, H. M.; Kwack, K.; Lee, Z. H.; Kim, H. H. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 2002, 30, 71–77. Liang, J. Y.; Wu, W. L.; Chen, Y. X.; Liu, H. C. The efficacy and potential mechanism of cnidium lactone to inhibit osteoclast differentiation. Artif. Cells Nanomed. Biotechnol. 2019, 47, 3087–3093. Soysa, N. S.; Alles, N. Osteoclast function and bone-resorbing activity: An overview. Biochem. Biophys. Res. Commun. 2016, 476, 115–120. Boyle, W. J.; Simonet, W. S.; Lacey, D. L. Osteoclast differentiation and activation. Nature 2003, 423, 337–342. Dumortier, C.; Danopoulos, S.; Velard, F.; Al Alam, D. Bone cells differentiation: How CFTR mutations may rule the game of stem cells commitment. Front. Cell Dev. Biol. 2021, 9, 611921. Guo, W.; Li, H. J.; Lou, Y.; Zhang, Y.; Wang, J.; Qian, M.; Wei, H. F.; Xiao, J. R.; Xu, Y. J. Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation. J. Orthop. Translat. 2021, 28, 148–158. Bobo, D.; Robinson, K. J.; Islam, J.; Thurecht, K. J.; Corrie, S. R. Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm. Res. 2016, 33, 2373–2387. Dang, L.; Liu, J.; Li, F. F.; Wang, L. Y.; Li, D. F.; Guo, B. S.; He, X. J.; Jiang, F.; Liang, C.; Liu, B. et al. Targeted delivery systems for molecular therapy in skeletal disorders. Int. J. Mol. Sci. 2016, 17, 428. Waldrep, J. C.; Gilbert, B. E.; Knight, C. M.; Black, M. B.; Scherer, P. W.; Knight, V.; Eschenbacher, W. Pulmonary delivery of beclomethasone liposome aerosol in volunteers: Tolerance and safety. Chest 1997, 111, 316–323. Chang, M. L.; Lu, S. S.; Zhang, F.; Zuo, T. T.; Guan, Y. Y.; Wei, T.; Shao, W.; Lin, G. M. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting. Colloids Surf. B: Biointerfaces 2015, 129, 175–182. Wieland, K.; Ramer, G.; Weiss, V. U.; Allmaier, G.; Lendl, B.; Centrone, A. Nanoscale chemical imaging of individual chemotherapeutic cytarabine-loaded liposomal nanocarriers. Nano Res 2019, 12, 197–203. Wang, D.; Sima, M.; Lee Mosley, R.; Davda, J. P.; Tietze, N.; Miller, S. C.; Gwilt, P. R.; Kopečková, P.; Kopeček, J. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol. Pharm. 2006, 3, 717–725. Wang, D.; Miller, S.; Sima, M.; Kopečková, P.; Kopeček, J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug. Chem. 2003, 14, 853–859.